Rhythm Pharmaceuticals price target raised to $80 from $77 at Canaccord

Canaccord analyst Whitney Ijem raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $80 from $77 and keeps a Buy rating on the shares. The firm said they delivered a slight beat this quarter, pointing to continued slow and steady progress in BBS, as the co works improve the drop-off rate, expand the label and enter into new OUS markets.